Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 04, 2021	Mar. 29, 2020
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities	[1]	$ 372	$ (274)
Allogene and BioNTech [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		409
Allogene [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities			(134)
BioNTech [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Proceeds from collaborators		$ 188
Disposed of by Sale [Member] | CK1 assets sold to Biogen, Inc [Member]
Loss Contingencies [Line Items]
Consideration transferred			$ 75

[1] Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.